Reeve Emma has demonstrated a clear selling bias in recent transactions involving PTC Therapeutics (PTCT), with no recorded purchases over the past several months. Since October 2025, Emma has executed 15 sales totaling approximately $5.16 million, with the largest single transaction occurring on November 21, 2025, when shares worth $795,000 were sold alongside an additional $511,600 in derivative transactions. The selling activity has been consistent, with notable transactions including an $834,000 sale on October 30, 2025, and a $546,308.50 sale on November 12, 2025. Smaller but frequent disposals were also recorded in early October 2025, with multiple sales ranging from $107,088 to $303,419.19.
Emma’s trading history shows an exclusive focus on PTCT, with no activity in other companies. The pattern suggests a steady reduction in exposure to the biopharmaceutical firm, with the most recent sales occurring on January 5, 2026, totaling $55,784 in stock and $34,160.36 in derivative transactions. While Emma has accumulated $2.58 million in historical buys, the recent trend is decisively weighted toward divestment. The absence of any recent purchases, combined with the frequency and scale of sales, indicates a sustained move to liquidate PTCT holdings over the past several months.
AI-assisted summary